COL18A1 and systemic sclerosis: Endostatin is released during ischemia-reperfusion and hypoxia [42–44] and hence it may be postulated that in preclinical SSc this molecule is a marker of a more severe form of vasculopathy, as well as an anti-angiogenic factor that promotes disease progression.